Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; Therapeutic Use
- Acronyms SOTA-CROSS HCM
- 17 Jan 2025 Status changed from not yet recruiting to recruiting.
- 21 Nov 2024 Planned initiation date changed from 1 Sep 2024 to 1 Dec 2024.
- 31 May 2024 New trial record